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Background
Peginterferon–ribavirin therapy is the current standard of care for chronic infection 
with hepatitis C virus (HCV). The rate of sustained virologic response has been below 
50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease in-
hibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies.
Methods
We conducted a double-blind study in which previously untreated adults with HCV 
genotype 1 infection were randomly assigned to one of three groups. In all three 
groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-
in period). Subsequently, group 1 (the control group) received placebo plus pegin-
terferon–ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon–
ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 
8 and 24 received placebo plus peginterferon–ribavirin for an additional 20 weeks; 
and group 3 received boceprevir plus peginterferon–ribavirin for 44 weeks. Nonblack 
patients and black patients were enrolled and analyzed separately.
Results
A total of 938 nonblack and 159 black patients were treated. In the nonblack cohort, 
a sustained virologic response was achieved in 125 of the 311 patients (40%) in group 
1, in 211 of the 316 patients (67%) in group 2 (P<0.001), and in 213 of the 311 patients 
(68%) in group 3 (P<0.001). In the black cohort, a sustained virologic response was 
achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in 
group 2 (P = 0.04), and in 29 of the 55 patients (53%) in group 3 (P = 0.004). In group 
2, a total of 44% of patients received peginterferon–ribavirin for 28 weeks. Anemia 
led to dose reductions in 13% of controls and 21% of boceprevir recipients, with 
discontinuations in 1% and 2%, respectively.
Conclusions
The addition of boceprevir to standard therapy with peginterferon–ribavirin, as com-
pared with standard therapy alone, significantly increased the rates of sustained vi-
rologic response in previously untreated adults with chronic HCV genotype 1 infec-
tion. The rates were similar with 24 weeks and 44 weeks of boceprevir. (Funded by 
Schering-Plough [now Merck]; SPRINT-2 ClinicalTrials.gov number, NCT00705432.)
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hronic infection with the hepati-
tis C virus (HCV) affects more than 170 
million people worldwide.1,2 Rates of sus-
tained virologic response associated with peg-
interferon–ribavirin therapy remain below 50% 
and are often less than 30% among patients who 
have HCV genotype 1 infection and certain base-
line characteristics, such as advanced fibrosis, dia-
betes, coinfection with the human immunodefi-
ciency virus (HIV), or African heritage.3-9 Recent 
efforts to improve the rate of sustained virologic 
response have focused on oral direct-acting anti-
viral agents.10-13
Boceprevir is a linear peptidomimetic keto-
amide serine protease inhibitor that binds revers-
ibly to the HCV nonstructural 3 (NS3) active site.14 
Like other protease inhibitors, boceprevir must be 
given with peginterferon–ribavirin to minimize the 
emergence of viral resistance.15,16 In the SPRINT-2 
(Serine Protease Inhibitor Therapy 2) trial, we ex-
amined whether the addition of boceprevir to 
standard therapy could improve the rates of sus-
tained virologic response in previously untreated 
patients infected with HCV genotype 1.
Methods
Study Design
A detailed description of the study methods is 
provided in the Supplementary Appendix (avail-
able with the full text of this article at NEJM.org). 
We conducted a phase 3, international, random-
ized, placebo-controlled study comparing the safe-
ty and efficacy of standard therapy with peginter-
feron alfa-2b and ribavirin (PegIntron and Rebetol, 
respectively; Merck) with the safety and efficacy of 
two treatment regimens in which boceprevir was 
added after a lead-in period of treatment with 
peginterferon–ribavirin alone (Fig. 1). Because of 
the marked difference in rates of sustained viro-
logic response between blacks and nonblacks,7 
self-identified blacks and nonblacks were enrolled 
separately into two cohorts.
The sponsor, patients, and study personnel were 
unaware of the assignment to the boceprevir or 
placebo group; the use of peginterferon and riba-
virin was open label. The trial was conducted in 
accordance with the principles of Good Clinical 
Practice and the study protocol (including the data 
analysis plan; available at NEJM.org); the study 
design was approved by the appropriate institu-
tional review boards and regulatory agencies. 
Each participant provided written informed con-
sent before undergoing any study-related proce-
dure. The trial was designed, managed, and ana-
lyzed by the industry authors in conjunction with 
the academic authors under the oversight of an 
independent data review advisory board. The aca-
demic authors had full access to all the data. The 
core writing team consisted of the principal aca-
demic author and all the industry authors, who 
were also responsible for the decision to submit 
the manuscript for publication, before which the 
sponsor reviewed a draft. Each author vouches for 
the fidelity of the trial conduct to the protocol and 
the completeness and accuracy of the results and 
data analyses.
Enrolled patients in each cohort were ran-
domly assigned, in a 1:1:1 ratio and by means of 
an interactive voice-response system, to one of the 
three treatment groups, after stratification on the 
basis of the baseline HCV RNA level (≤400,000 vs. 
>400,000 IU per milliliter) and HCV genotype 1 
subtype (1a vs. 1b). Patients in whom HCV could 
not be subtyped were randomly assigned to a 
treatment group within their HCV RNA stratum.
Selection of Patients
Eligibility criteria were a history of no previous 
treatment for HCV infection, age of 18 years or 
older, weight of 40 to 125 kg, chronic infection 
with HCV genotype 1, and plasma HCV RNA level 
of 10,000 IU per milliliter or greater. Exclusion 
criteria were liver disease of other cause, decom-
pensated cirrhosis, renal insufficiency, HIV or 
hepatitis B infection, pregnancy or current breast-
feeding, and active cancer. Liver-biopsy specimens 
were assigned Metavir fibrosis scores and steato-
sis scores by a single academic author who is a 
pathologist and was unaware of the assignment to 
the boceprevir or placebo group. The HCV geno-
type 1 subtype was determined with the use of the 
Trugene assay (Bayer Diagnostics) for purposes of 
randomization and by sequencing of the nonstruc-
tural 5B (NS5B) region (Virco) for subsequent 
analyses.
Study Regimens
Peginterferon alfa-2b was administered subcuta-
neously at a dose of 1.5 µg per kilogram of body 
weight once weekly; and weight-based oral riba-
virin was administered at a total dose of 600 to 
1400 mg per day in divided doses, given in the 
morning and evening. Treatment with boceprevir 
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consisted of oral administration at a dose of 
800 mg three times daily (to be taken with food 
and at an interval of 7 to 9 hours between doses) 
in four capsules of 200 mg each. Placebo was 
matched to boceprevir.
All patients received peginterferon–ribavirin 
during the 4-week lead-in period (Fig. 1). Patients 
randomly assigned to group 1 (the standard of 
care) received peginterferon–ribavirin treatment 
for 44 weeks after the lead-in period, as well as 
thrice-daily placebo beginning at week 5. Patients 
randomly assigned to group 2 (response-guided 
therapy) received peginterferon–ribavirin plus bo-
ceprevir for a total of 24 weeks after the lead-in 
period; if HCV RNA levels were undetectable from 
week 8 through week 24, treatment was consid-
ered complete, but if HCV RNA levels were detect-
able at any visit from week 8 up to but not in-
cluding week 24, peginterferon–ribavirin was 
continued, and placebo was administered, at week 
28 through week 48. Patients randomly assigned 
to group 3 (fixed-duration therapy) received peg-
interferon–ribavirin plus oral boceprevir for 44 
weeks after the lead-in period.
In all three groups, the study treatment was 
discontinued for all patients with a detectable 
HCV RNA level at week 24, according to a stan-
dard futility rule. Boceprevir was given for 24 
weeks in group 2 and 44 weeks in group 3. All 
patients were followed through week 72.
Viral breakthrough was defined as achievement 
of an undetectable HCV RNA level and subse-
quent occurrence of an HCV RNA level greater 
than 1000 IU per milliliter. Incomplete virologic 
response and rebound was defined as an increase 
of 1 log10 IU per milliliter in the HCV RNA level 
from the nadir, with an HCV RNA level greater 
than 1000 IU per milliliter (if both samples being 
compared were collected the same number of 
days after the last peginterferon injection). In 
cases in which the timing between the peginter-
feron injection and the HCV RNA sample collec-
tion was different for the two samples, an increase 
of 2 log10 IU per milliliter was required to meet 
Follow-upPlacebo and peginterferon–ribavirin
Peginterferon–
ribavirin
Boceprevir and
peginterferon–ribavirin
Boceprevir and peginterferon–ribavirin
Undetectable HCV RNA levels at wk 8–24
Detectable HCV RNA levels at wk 8–24 
Placebo and
peginterferon–ribavirin
Follow-up
Follow-up
Follow-up
Peginterferon–
ribavirin
Peginterferon–
ribavirin
40 24 28 48 72
Week
Control
Experimental
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Figure 1. Study Design.
Patients in each of the two study cohorts were randomly assigned to a treatment group in a 1:1:1 ratio. All patients 
received peginterferon alfa-2b–ribavirin during the 4-week lead-in period. Subsequently, patients assigned to group 1 
received 44 weeks of peginterferon alfa-2b–ribavirin as well as a placebo capsule; patients assigned to group 3 re-
ceived peginterferon–ribavirin as well as boceprevir for 44 weeks; and patients assigned to group 2 received pegin-
terferon–ribavirin as well as boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level 
at any visit between weeks 8 and 24 received peginterferon–ribavirin plus placebo from week 28 to week 48. Treat-
ment was discontinued for reasons of futility if the HCV RNA level was detectable at the week 24 visit. Boceprevir 
was given for a total of 24 weeks in group 2 (irrespective of the rapidity of the decrease in the viral load) and, unless 
futility had been shown, for a total of 44 weeks in group 3. The x-axis numbers are not to scale.
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this criterion. If a patient had virologic break-
through or an incomplete virologic response and 
rebound while receiving therapy, boceprevir treat-
ment could be discontinued, but peginter fer on–
ribavirin could be continued for up to 48 weeks 
with appropriate clinical follow-up.
Efficacy Assessment
Plasma HCV RNA levels were measured with the 
use of the TaqMan 2.0 assay (Roche Diagnostics), 
which has lower limits of quantification and de-
tection of 25 and 9.3 IU per milliliter, respectively; 
the lower limit of detection was used for decision 
making at various points throughout the study. 
HCV RNA testing was performed at the screening 
visit, at baseline, every 2 weeks through week 12, 
and at weeks 16, 20, 24, 28, 34, 40, 48, 52, 60, and 
72 (depending on the treatment duration). Patients 
in whom study therapy was stopped because of fu-
tility were considered to have had treatment failure.
Safety Assessment
Adverse events were graded by investigators ac-
cording to a modified World Health Organization 
grading system. Non–life-threatening hematolog-
ic adverse events were managed by means of dose 
reduction or administration of hematopoietic 
growth factors (or both). Reduction of the ribavi-
rin dose or administration of erythropoietin was 
recommended when the hemoglobin level dropped 
to less than 10 g per deciliter, but these decisions 
were made at the discretion of the investigators; 
erythropoietin was to be stopped if the hemoglo-
bin level rebounded to 12 g per deciliter or greater.
Statistical Analysis
The trial was designed as a superiority study to 
detect differences in the rates of sustained viro-
logic response with either of the two boceprevir 
regimens (group 2 or group 3) as compared with 
standard therapy alone (group 1). The primary 
analyses involved all patients who had received at 
least one dose of any study medication; key sec-
ondary efficacy analyses were conducted for the 
modified intention-to-treat population, consisting 
of patients who completed the lead-in period of 
treatment and received at least one dose of bo-
ceprevir or placebo. Rates of response were de-
termined separately (per protocol) for the non-
black cohort and the black cohort.
The protocol-specified primary efficacy end 
point was a sustained virologic response, defined 
as undetectable HCV RNA levels for 24 weeks 
after the completion of therapy. If HCV RNA mea-
surements for this time point or later were miss-
ing, the 12-week post-treatment measurement was 
used. Relapse was defined as the occurrence of an 
undetectable HCV RNA level at the end of treat-
ment but a detectable HCV RNA level at some 
point during the follow-up period.
Within-cohort comparisons were performed 
with the use of the two-sided Cochran–Mantel–
Haenszel chi-square test (after adjustment for 
baseline stratification factors). A step-down ap-
proach was applied to hypothesis testing. Group 3 
was first compared with group 1. If the resultant 
P value was 0.05 or less, the superiority of fixed-
duration therapy including boceprevir over stan-
dard therapy would be supported, and group 2 
would then be compared with group 1. If this 
P value was also 0.05 or less, the superiority of 
response-guided therapy including boceprevir over 
standard therapy would likewise be established.
Secondary analyses were to be conducted only 
if the primary comparisons showed significant 
differences. Formal hypothesis testing comparing 
the two boceprevir groups was not specified in the 
protocol. A multivariate logistic-regression model 
that included baseline characteristics and treat-
ment group was used to identify predictors of 
sustained virologic response. A stepwise proce-
dure was used to identify independent covariates, 
with an alpha level of 0.05 as the threshold level 
for variables to be entered into, and retained in, 
the model.
Assuming a rate of sustained virologic re-
sponse of 45% in group 1 of the nonblack cohort, 
we calculated that 310 subjects per group would 
need to be enrolled for the study to have a statis-
tical power of 90% to detect an absolute increase 
of 13 percentage points in the rate of sustained 
virologic response in group 3 as compared with 
group 1, with the use of a two-sided chi-square 
test and an alpha level of 0.05. Assuming a rate 
of sustained virologic response of 50% in the 
black cohort overall, 50 patients per group, and 
the use of a two-sided 95% confidence interval, 
we estimated that the true rate of a sustained 
virologic response in the black population could 
be estimated, within ±14%, for each of the three 
treatment groups.
Safety analyses included all patients who had 
been randomly assigned to a study group and had 
received at least one dose of any study medication.
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Results
Study Patients
A total of 1246 and 226 patients were screened for 
the nonblack cohort and the black cohort, respec-
tively, of whom 940 nonblack patients and 159 
black patients were randomly assigned to a treat-
ment group from August 2008 through January 
2009 (Fig. S1 in the Supplementary Appendix). 
Two patients in the nonblack cohort did not re-
ceive any study drug and were not included in the 
analyses. All the other randomly assigned patients 
received at least 1 dose of study medication. 
Baseline characteristics are shown in Table 1.
A total of 49 patients discontinued the pegin-
terferon–ribavirin therapy during the lead-in period 
and did not receive boceprevir or placebo. Discon-
tinuation for reasons of futility at week 24 occurred 
Table 1. Selected Baseline Characteristics of Patients Who Received at Least One Dose of Study Medication, According to Cohort 
and Treatment Group.*
Characteristic Nonblack Cohort Black Cohort Both Cohorts
Group 1 
(N = 311)
Group 2 
(N = 316)
Group 3 
(N = 311)
Group 1 
(N = 52)
Group 2 
(N = 52)
Group 3 
(N = 55)
Group 1 
(N = 363)
Group 2  
(N = 368)
Group 3 
(N = 366)
Age — yr 48±10 49±9 49±9 51±9 52±8 51±7 49±10 50±9 49±9
Male sex — no. (%) 171 (55) 200 (63) 188 (60) 35 (67) 29 (56) 33 (60) 206 (57) 229 (62) 221 (60)
Race — no. (%)†
White 296 (95) 304 (96) 295 (95) 296 (82) 304 (83) 295 (81)
Black 52 (100) 52 (100) 55 (100) 52 (14) 52 (14) 55 (15)
Asian 9 (3) 4 (1) 8 (3) 9 (2) 4 (1) 8 (2)
Other 6 (2) 8 (3) 8 (3) 0 0 0 6 (2) 8 (2) 8 (2)
Region — no. (%)
North America 203 (65) 226 (72) 218 (70) 51 (98) 51 (98) 52 (95) 254 (70) 277 (75) 270 (74)
Europe 98 (32) 78 (25) 83 (27) 1 (2) 1 (2) 3 (5) 99 (27) 79 (21) 86 (23)
Latin America 10 (3) 12 (4) 10 (3) 0 0 0 10 (3) 12 (3) 10 (3)
Weight — kg 79±16 82±17 80±17 87±14 86±15 91±18 80±16 82±17 82±17
HCV subtype — no. (%)‡
1a 186 (60) 195 (62) 197 (63) 41 (79) 39 (75) 40 (73) 227 (63) 234 (64) 237 (65)
1b 112 (36) 111 (35) 104 (33) 9 (17) 13 (25) 13 (24) 121 (33) 124 (34) 117 (32)
Missing data 13 (4) 10 (3) 10 (3) 2 (4) 0 2 (4) 15 (4) 10 (3) 12 (3)
HCV RNA level — no. (%)
>400,000 IU/ml 285 (92) 287 (91) 288 (93) 52 (100) 49 (94) 53 (96) 337 (93) 336 (91) 341 (93)
>800,000 IU/ml 258 (83) 268 (85) 262 (84) 50 (96) 46 (88) 51 (93) 308 (85) 314 (85) 313 (86)
Metavir fibrosis score —  
no. (%)§
0, 1, or 2 277 (89) 279 (88) 265 (85) 51 (98) 40 (77) 48 (87) 328 (90) 319 (87) 313 (86)
3 or 4 23 (7) 26 (8) 36 (12) 1 (2) 8 (15) 6 (11) 24 (7) 34 (9) 42 (11)
Missing data 11 (4) 11 (3) 10 (3) 0 4 (8) 1 (1) 11 (3) 15 (4) 11 (3)
Steatosis — no. (%)§ 192 (62) 213 (67) 208 (67) 32 (62) 33 (63) 39 (71) 224 (62) 246 (67) 247 (67)
* Plus–minus values are means ±SD. Boceprevir was given for 24 weeks in group 2 and for 44 weeks in group 3, irrespective of the rapidity of 
achievement of an undetectable HCV RNA level. See Table S1 in the Supplementary Appendix for a complete list of baseline characteristics.
† Race was self-reported. Hispanic or Latino was given as a second self-identification by 8 to 13% of the patients in each treatment group in 
the nonblack cohort and in one patient in the black cohort.
‡ The HCV subtype was ascertained by sequencing of the nonstructural 5B region.
§ Metavir scores and steatosis were determined on the basis of assessment of liver-biopsy specimens by a single pathologist who was unaware 
of the assignment to the boceprevir or placebo group. Possible fibrosis scores are as follows: 0 (indicating no fibrosis), 1 (indicating portal fi-
brosis without septa), 2 (indicating portal fibrosis with few septa), 3 (indicating numerous septa without cirrhosis), and 4 (indicating cirrhosis). 
Steatosis was analyzed as being present or absent.
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Table 2. Rates of Virologic Responses among Patients Who Received at Least One Dose of Any Study Medication, 
According to Cohort and Treatment Group.*
Characteristic Nonblack Cohort
Group 1 
(N = 311)
Group 2 
(N = 316)
P Value for 
Group 2 vs. 
Group 1
Group 3 
(N = 311)
P Value for 
Group 3 vs. 
Group 1
no. of patients/total no. (%) no. of patients/total no. (%)
Response at end of therapy† 176/311 (57) 235/316 (74) <0.001 241/311 (77) <0.001
Rate of relapse‡ 37/162 (23) 21/232 (9) <0.001 18/230 (8) <0.001
Sustained virologic response§
All patients who received treatment 125/311 (40) 211/316 (67) <0.001 213/311 (68) <0.001
Modified ITT population 125/297 (42) 211/303 (70) <0.001 213/299 (71) <0.001
HCV RNA level at wk 4
Undetectable or decreased  
by ≥1 log10 IU/ml
121/234 (52) 187/228 (82) <0.001 178/218 (82) <0.001
Decreased by <1 log10 IU/ml 3/62 (5) 21/73 (29) <0.001 31/79 (39) <0.001
HCV RNA detectability at wk 4
Undetectable¶ 27/28 (96) 16/18 (89) 0.55 18/20 (90) 0.56
Detectable‖ 97/268 (36) 192/283 (68) <0.001 191/277 (69) <0.001
HCV RNA detectability at wk 8
Undetectable 48/56 (86) 170/190 (89) 0.47 166/182 (91) 0.31
Detectable‖ 73/233 (31) 38/104 (37) 0.38 44/102 (43) 0.046
HCV RNA detectability wk 8 through wk 24
Undetectable 37/40 (93) 143/147 (97) 0.17 137/142 (96) 0.38
Detectable** 78/118 (66) 52/70 (74) 0.26 48/65 (74) 0.32
Baseline Metavir fibrosis score††
0, 1, or 2 111/277 (40) 194/279 (70) <0.001 186/265 (70) <0.001
3 or 4 9/23 (39) 13/26 (50) 0.57 18/36 (50) 0.44
*  Boceprevir was given for 24 weeks in group 2 and for 44 weeks in group 3, irrespective of the rapidity of achievement 
of an undetectable HCV RNA level. P values were calculated for the rates of sustained virologic response with the use 
of the Cochran–Mantel–Haenszel chi-square test, with adjustment for prespecified stratification factors; P values for 
other response data were calculated by means of Fisher’s exact test. ITT denotes intention to treat.
†  Response at the end of therapy was defined as an undetectable HCV RNA level at the time that the study therapy was 
discontinued. The end of therapy was the actual (not assigned) end of treatment.
‡  Rate of relapse was defined as the proportion of patients with a detectable HCV RNA level at the end of the follow-up 
period, as calculated among the patients with an undetectable level at the end of the treatment period who did not 
have missing follow-up data.
§  Sustained virologic response was defined as an undetectable HCV RNA level at the end of the follow-up period. The 
12-week post-treatment HCV RNA level was used (as specified in the protocol) if the 24-week post-treatment level 
was not available. A sensitivity analysis was performed on data from only patients with an undetectable HCV RNA lev-
el documented at 24 weeks after treatment: the rates of sustained virologic response for groups 1, 2, and 3 in the 
nonblack cohort were 39%, 66%, and 68%, respectively, and the rates in the black cohort were 21%, 42%, and 51%, 
respectively.
¶  In the black cohort, the sample was too small to calculate the P value for the comparison between group 2 and group 1.
‖  Detectable HCV RNA was defined as an HCV RNA level above the limit of detection (9.3 IU per milliliter) at the speci-
fied week in patients for whom HCV RNA values were available.
** HCV RNA detectability at weeks 8 through 24 was ascertained only in patients receiving more than 28 weeks of thera-
py. Only 22% of patients (82 of 368) in group 2 were assigned a 48-week fixed treatment duration.
†† The Metavir fibrosis scores were determined on the basis of assessment of liver-biopsy specimens by a single pathol-
ogist who was unaware of the assignment to the boceprevir or placebo group. Possible fibrosis scores are as follows: 
0 (indicating no fibrosis), 1 (indicating portal fibrosis without septa), 2 (indicating portal fibrosis with few septa),  
3 (indicating numerous septa without cirrhosis), and 4 (indicating cirrhosis).
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in 84 of 311 patients (27%), 24 of 316 patients 
(8%), and 28 of 311 patients (9%) in the non-
black cohort and in 24 of 52 patients (46%), 9 of 
52 patients (17%), and 8 of 55 patients (15%) in the 
black cohort in groups 1, 2, and 3, respectively.
Efficacy
Response rates were significantly higher among 
patients receiving a boceprevir-containing regimen 
than among controls (Table 2). Among nonblacks, 
the rate of a sustained virologic response was 
40% with the standard of care and was signifi-
cantly higher (P<0.001) in both boceprevir groups 
— 67% in group 2 and 68% in group 3 — for 
relative increases of 68% and 70%, respectively, 
over control rates. Among blacks, the rate of a 
sustained virologic response was 23% in group 1, 
42% in group 2 (P = 0.04, vs. group 1), and 53% in 
group 3 (P = 0.004, vs. group 1). In a modified 
intention-to-treat analysis that included all non-
blacks receiving at least one dose of boceprevir or 
placebo, the respective rates of sustained virologic 
response in groups 1, 2, and 3 were 42%, 70% 
(P<0.001, vs. group 1), and 71% (P<0.001, vs. group 
1), the corresponding rates among blacks were 
26%, 47% (P = 0.04, vs. group 1), and 53% (P = 0.01, 
vs. group 1). In the nonblack cohort, viral break-
through occurred in 1 to 2% of patients in each 
treatment group, whereas rates of relapse were 
lower in the two boceprevir groups than in the 
standard-therapy group. The numbers of events in 
the smaller black cohort were too few to permit 
comparison between treatment groups.
The 4-week lead-in period of peginterferon–
Black Cohort Both Cohorts
Group 1 
(N = 52)
Group 2 
(N = 52)
P Value for 
Group 2 vs. 
Group 1
Group 3 
(N = 55)
P Value for 
Group 3 vs. 
Group 1
Group 1 
(N = 363)
Group 2 
(N = 368)
P Value for 
Group 2 vs. 
Group 1
Group 3 
(N = 366)
P Value for 
Group 3 vs. 
Group 1
no. of patients/total no. (%)
no. of patients/
total no. (%) no. of patients/total no. (%)
no. of patients/
total no. (%)
15/52 (29) 26/52 (50) 0.04 36/55 (65) <0.001 191/363 (53) 261/368 (71) <0.001 277/366 (76) <0.001
2/14 (14) 3/25 (12) 1.00 6/35 (17) 1.00 39/176 (22) 24/257 (9) <0.001 24/265 (9) <0.001
12/52 (23) 22/52 (42) 0.04 29/55 (53) 0.004 137/363 (38) 233/368 (63) <0.001 242/366 (66) <0.001
12/47 (26) 22/47 (47) 0.04 29/55 (53) 0.001 137/344 (40) 233/350 (67) <0.001 242/354 (68) <0.001
12/26 (46) 16/24 (67) 0.17 22/36 (61) 0.30 133/260 (51) 203/252 (81) <0.001 200/254 (79) <0.001
0/21 6/24 (25) 0.02 5/16 (31) 0.01 3/83 (4) 27/97 (28) <0.001 36/95 (38) <0.001
2/2 (100) 1/1 (100) 0/0 29/30 (97) 17/19 (89) 0.55 18/20 (90) 0.56
10/45 (22) 21/47 (45) 0.03 27/52 (52) 0.003 107/313 (34) 213/330 (65) <0.001 218/329 (66) <0.001
3/4 (75) 14/18 (78) 1.00 18/22 (82) 0.57 51/60 (85) 184/208 (88) 0.50 184/204 (90) 0.25
8/38 (21) 8/25 (32) 0.38 8/29 (28) 0.57 81/271 (30) 46/129 (36) 0.25 52/131 (40) 0.06
3/3 (100) 13/15 (87) 0.99 18/19 (95) 1.00 40/43 (93) 156/162 (96) 0.40 155/161 (96) 0.40
8/13 (62) 7/12 (58) 1.00 7/8 (88) 0.36 86/131 (66) 59/82 (72) 0.37 55/73 (75) 0.16
12/51 (24) 19/40 (48) 0.03 25/48 (52) 0.004 123/328 (38) 213/319 (67) <0.001 211/313 (67) <0.001
0/1 1/8 (12) 1.00 4/6 (67) 0.43 9/24 (38) 14/34 (41) 1.00 22/42 (52) 0.31
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ribavirin treatment allowed for the assessment of 
interferon responsiveness and its relationship to 
sustained virologic response. At week 4, 23% of 
nonblacks and 38% of blacks had a decrease of 
less than 1 log10 IU per milliliter in the HCV RNA 
level from baseline, which was associated with 
lower rates of sustained virologic response (Ta-
ble 2) and higher rates of boceprevir-resistance–
associated variants (genotypic mutations of the 
protease conferring reduced sensitivity to bocepre-
vir) (Table 3) than was a decrease of 1 log10 IU per 
milliliter or more in the HCV RNA level, regard-
less of the treatment group. However, whether the 
decrease in the HCV RNA level at week 4 was more 
or less than 1 log10 IU per milliliter, rates of sus-
tained virologic response were consistently higher 
in the boceprevir groups than in the control group.
The percentages of patients with undetectable 
HCV RNA levels at week 8 who had a sustained 
virologic response were high, irrespective of the 
treatment regimen, but this response at week 8 
occurred approximately three times as often in 
the boceprevir groups as in the control group. At 
this time point, the patients had received bo-
ceprevir or placebo for 4 weeks and peginter-
feron–ribavirin for 8 weeks.
The rates of sustained virologic response 
among nonblacks were similar in group 2 (67%) 
and in group 3 (68%), whereas among blacks they 
were 42% and 53%, respectively. Among nonblack 
boceprevir recipients whose HCV RNA levels be-
came undetectable by week 8 (60%) and those with 
undetectable HCV RNA levels through week 24 
(47%), the rate of sustained virologic response was 
97% in group 2 (which had received 24 weeks of 
boceprevir and a total of 28 weeks of therapy) and 
96% in group 3 (which had received 44 weeks of 
boceprevir and a total of 48 weeks of therapy) 
(Table 2).
In group 2, a total of 22% of the patients with 
a detectable HCV RNA level between week 8 and 
week 24 received therapy for more than 28 
weeks. Among patients in whom HCV RNA levels 
were still detectable at week 8, rates of sustained 
virologic response were 74% in group 2 (after re-
ceiving 24 weeks of boceprevir) as well as in 
group 3 (after receiving 44 weeks of boceprevir).
Predictors of sustained virologic response were 
identical in models for each cohort. Rates of sus-
tained virologic response in patients with ad-
vanced fibrosis were lower than in those with 
mild fibrosis, although the numbers of patients 
with a Metavir fibrosis score of 3 or 4 (indicating 
bridging fibrosis or cirrhosis) were small, par-
ticularly in the black cohort (Table 4). In an ex-
panded model that included virologic responses 
during the treatment period, a decrease in the HCV 
RNA level by 1 log10 IU per milliliter or more at 
the end of the 4-week lead-in period was strong-
ly predictive of a sustained virologic response 
(odds ratio vs. a decrease of <1 log10 IU per mil-
liliter, 9.0; 95% confidence interval, 6.3 to 12.8; 
P<0.001). In general, subgroup analyses across a 
range of baseline factors favored group 2 and 
group 3 over group 1, with no consistent differ-
ences between groups 2 and 3 (Fig. S2 in the 
Supplementary Appendix). For groups 1, 2, and 3 
in the nonblack cohort, rates of sustained viro-
logic response were 33%, 64%, and 59%, respec-
tively, among patients with a hemoglobin level of 
10 g per deciliter or higher during the treatment 
period, as compared with 60%, 72%, and 79%, 
respectively, among patients with a nadir hemoglo-
bin level of less than 10 g per deciliter during the 
treatment period.
Safety
Adverse events occurred in more than 98% of the 
study patients, with serious adverse events in 9%, 
11%, and 12% of patients in groups 1, 2, and 3, 
respectively (Table S2 in the Supplementary Ap-
pendix). There were six deaths during the study: 
four patients in the control group died, as did two 
patients in the boceprevir groups. Two suicides 
(one in group 1 and one in group 2) were judged 
to have possibly been related to peginterferon. No 
other deaths were considered to be drug-related.
Fatigue, headache, and nausea were the most 
common clinical adverse events in all treatment 
groups (Table 3). Dysgeusia occurred more than 
twice as often in boceprevir recipients than in 
controls. Anemia was reported as an adverse 
event in 29% of controls and 49% of boceprevir 
recipients. Anemia was classified as grade 1 in 
36% of controls, grade 2 in 17%, grade 3 in 2%, 
and grade 4 in 0%; the respective percentages 
among boceprevir recipients were 43%, 31%, 3%, 
and 1%. Four patients in group 1 discontinued the 
study owing to anemia, as compared with six pa-
tients in group 2 and seven patients in group 3. 
Overall, 13% of controls and 21% of boceprevir 
recipients required dose reductions because of 
anemia. Erythropoietin was administered in 24% 
of controls and 43% of boceprevir recipients. A 
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total of 85% and 86% of patients in group 2 and 
group 3, respectively, had neutropenia of grade 1 
to 4, as compared with 77% of those in the con-
trol group; 28% and 33% of patients in groups 1 
and 2, respectively, had grade 1 to 4 thrombocy-
topenia, as compared with 13% of controls.
Table 3. Common Clinical Adverse Events, Resistance-Associated HCV Variants, and Hematologic Abnormalities, According to Treatment 
Group.*
Adverse Event
Group 1 
(N = 363)
Group 2 
(N = 368)
P Value for Group 2 
vs. Group 1
Group 3 
(N = 366)
P Value for Group 3 
vs. Group 1
Investigator-reported clinical adverse events — no. (%)
Fatigue 217 (60) 196 (53) 0.09 209 (57) 0.50
Headache 153 (42) 168 (46) 0.37 167 (46) 0.37
Nausea 153 (42) 175 (48) 0.16 159 (43) 0.76
Anemia 107 (29) 182 (49) <0.001 179 (49) <0.001
Pyrexia 121 (33) 123 (33) 0.99 118 (32) 0.81
Chills 102 (28) 134 (36) 0.02 121 (33) 0.15
Dysgeusia 64 (18) 137 (37) <0.001 156 (43) <0.001
Insomnia 118 (33) 117 (32) 0.87 122 (33) 0.81
Boceprevir-resistance–associated variants — no. (%)
Overall 59/350 (17) 52/354 (15)
HCV RNA level at wk 4
Decrease of ≥1 log10 IU/ml from baseline 10/232 (4) 13/231 (6)
Decrease of <1 log10 IU/ml from baseline 49/95 (52) 38/94 (40)
Hematologic variables — no. (%)
Decreased absolute neutrophil count
Grade 3: 500 to <750 per mm3 50 (14) 87 (24) <0.001 90 (25) <0.001
Grade 4: <500 per mm3 16 (4) 21 (6) 0.50 29 (8) 0.06
Use of granulocyte-stimulating agent 21 (6) 43 (12) 0.006 31 (8) 0.20
Decreased platelet count
Grade 3: 25,000 to <50,000 per mm3 5 (1) 11 (3) 0.21 13 (4) 0.09
Grade 4: <25,000 per mm3 0 1 (<1) 0.99 1 (<1) 0.99
Decreased hemoglobin concentration†
Grade 3: 6.5 to <8.0 g/dl 6 (2) 7 (2) 0.99 12 (3) 0.23
Grade 4: <6.5 g/dl 0 2 (1) 0.50 1 (<1) 0.99
Red-cell transfusion 2 (1) 11 (3) 0.02 9 (2) 0.06
Erythropoietin use
Patients 87 (24) 159 (43) <0.001 159 (43) <0.001
Days 0.01 0.005
Mean 121 94 156
Median 109 85 149
* The table lists (in decreasing order of overall frequency) all specified adverse events occurring during the treatment period or within 30 days 
after the end of treatment, regardless of the cause of the event, that were reported in 30% or more of patients in any of the three treatment 
groups. Table S2B in the Supplementary Appendix lists the adverse events reported in 15% or more of patients in any treatment group, as 
well as laboratory abnormalities of grade 0, 1, or 2. Terms are from the Medical Dictionary for Regulatory Activities (version 13.0). The nomi-
nal P values were calculated with the use of Fisher’s exact test for categorical variables and the t-test for continuous variables; they were not 
corrected for multiple comparisons.
† Toxicity grades for decreased hemoglobin levels are modified World Health Organization grades based on nadir hemoglobin levels during 
the treatment period.
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Discussion
SPRINT-2 compared two regimens of boceprevir 
added to peginterferon alfa-2b–ribavirin therapy 
(the standard of care) and the standard of care 
alone. Two distinct cohorts were enrolled on the 
basis of self-identified race (nonblack patients and 
black patients) to allow for an independent esti-
mate of rates of response among black patients, 
a group historically underrepresented in HCV-
treatment trials.
As compared with peginterferon alfa-2b–riba-
virin therapy alone, the addition of boceprevir 
significantly increased the rate of a sustained vi-
rologic response among previously untreated black 
and nonblack patients infected with HCV geno-
type 1, including those with a decrease of less 
than 1 log
10
 IU per milliliter in the HCV RNA 
level at week 4. Among nonblack patients, the 
combination therapy with boceprevir was associ-
ated with a relative increase of approximately 70% 
in the rates of sustained virologic response over 
standard therapy. Although lower among black 
patients than among nonblack patients, the rates 
of sustained virologic response with the boceprevir 
regimens were nearly double those with the stan-
dard of care. Patients with an undetectable HCV 
RNA level at week 8 had a higher rate of sus-
tained virologic response than patients with a 
detectable level at week 8, irrespective of treat-
ment regimen. Given the relatively small numbers 
of patients with cirrhosis in the trial, further 
study is warranted to define optimal therapy in 
this population.
Our study evaluated a response-guided treat-
ment strategy with individualized treatment du-
ration on the basis of the HCV RNA level be-
tween weeks 8 and 24. Patients in whom the HCV 
RNA level became undetectable by week 8 and 
remained so up to week 24 were given bocepre-
vir plus peginterferon–ribavirin for 24 weeks. The 
rates of sustained virologic response among 
both black and nonblack patients were signifi-
cantly higher with response-guided therapy than 
with standard treatment. Regardless of the viro-
logic response at week 4 or week 8, response-
guided therapy that included 24 weeks of bo-
ceprevir administration resulted in overall rates 
of sustained virologic response that were similar 
to those after 44 weeks of triple therapy. Patients 
who had undetectable HCV RNA levels by week 
8 had very high rates of sustained virologic re-
sponse as compared with patients who had de-
tectable levels between weeks 8 and 24. There 
were too few black patients in whom the HCV 
RNA level was detectable between weeks 8 and 
24 to conclusively define the optimal treatment 
for this population.
This trial featured the use of peginterferon–
ribavirin for 4 weeks (the lead-in period) before 
boceprevir was added. Theoretically, a lead-in 
phase would serve to lower HCV RNA levels be-
fore exposure to a protease inhibitor, thereby 
reducing the risk of viral breakthrough or resis-
tance to the direct-acting antiviral agent, as noted 
in a phase 2 study in which boceprevir with lead-
in therapy was compared with boceprevir without 
lead-in therapy.10 However, lead-in therapy has 
other benefits, such as allowing for assessment of 
the relationship between interferon responsive-
ness and subsequent sustained virologic response 
in patients receiving boceprevir. Patients with a 
poor response to interferon, defined as a reduc-
tion in the HCV RNA level of less than 1 log10 IU 
per milliliter after 4 weeks of peginterferon–riba-
Table 4. Odds Ratios for a Sustained Virologic Response, According to 
Predictor Variables.*
Variable†
Odds Ratio 
(95% CI) P Value‡
Treatment group
Group 3 vs. group 1 3.5 (2.6–4.9) <0.001
Group 2 vs. group 1 3.1 (2.3–4.3) <0.001
Black cohort vs. nonblack cohort§ 0.5 (0.3–0.7) <0.001
Baseline HCV RNA level ≤400,000 vs. 
>400,000 IU/ml
3.9 (2.1–7.1) <0.001
Age ≤40 vs. >40 yr 1.5 (1.0–2.1) 0.03
No cirrhosis vs. cirrhosis 2.5 (1.4–4.6) 0.003
Statin use vs. no statin use 3.4 (1.1–10.7) 0.04
* The odds ratios were estimated in a multivariate stepwise logistic-regression 
model that included baseline predictors of sustained virologic response in all 
treated patients (in the black and nonblack cohorts combined). CI denotes 
confidence interval.
† Only covariates remaining significant at an alpha level of 0.05 after adjust-
ment for the other variables were retained in the model and are listed in the 
table. Factors entered but not retained in the model were region, sex, age, 
weight, body-mass index, hepatitis C virus (HCV) genotype 1 subtype as as-
certained by means of the Trugene assay, hepatic steatosis, platelet count,  
alanine aminotransferase level, and Metavir fibrosis score at baseline. In an 
expanded model that included response data during the treatment period,  
an HCV RNA level at week 4 that was undetectable or that had decreased by  
1 log10 IU per milliliter or more from baseline (vs. a decrease of <1 log10 IU 
per milliliter) had the highest odds ratio: 9.0 (95% CI, 6.3 to 12.8; P<0.001).
‡ P values were calculated with the use of the chi-square test.
§ Race was self-reported.
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virin therapy, had sufficiently high rates of sus-
tained virologic response, as compared with the 
control group, to dispel concern that the addition 
of a protease inhibitor to the treatment regimen 
would be equivalent to functional monotherapy. 
However, these patients were less likely than pa-
tients with a robust response to interferon to have 
a sustained virologic response after boceprevir 
was added.17-19 Thus, patients who have a poor 
response to interferon may need to be monitored 
closely to determine who may benefit from better 
therapies, once they are available. Conversely, in 
patients with undetectable HCV RNA levels after 
the lead-in period, boceprevir administration may 
not result in a higher rate of sustained virologic 
response than that achieved with the use of peg-
interferon and ribavirin alone. The lead-in period 
can further serve to test both compliance and 
tolerability before exposure to a class of drugs to 
which resistance can develop.15,16
The regimens that included boceprevir were 
associated with increased rates of anemia, and 
nearly twice as many boceprevir recipients as con-
trols had a hemoglobin level of less than 9.5 g per 
deciliter or received erythropoietin (43% vs. 24%). 
Among patients receiving erythropoietin, the av-
erage duration of use was shortest in group 2. 
Neither the incidence of serious adverse events 
nor the frequency of discontinuation owing to an 
adverse event differed significantly between pa-
tients receiving boceprevir and those receiving 
standard therapy. The rate of a sustained viro-
logic response was significantly greater with bo-
ceprevir plus peginterferon–ribavirin than with 
peginterferon–ribavirin alone among both black 
and nonblack patients.
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